Surgical treatment of secondary postuveal glaucoma by microinvasive non-penetrating deep sclerectomy with Healaflow implant injection: clinical case

The study aim was to evaluate the effectiveness of treatment of postveal uncompensated glaucoma in a patient with chronic infectious uveitis by microinvasive non-penetrating deep sclerectomy using drainage implant Healaflow. Material and methods. In a patient with the history of chronic uveitis, for the purpose of surgical treatment of secondary uncompensated post-uveal glaucoma, a microinvasive non-penetrating deep sclerectomy with the introduction of Healaflow has been performed in order to stabilize intraocular pressure, visual acuity and visual field. Healaflow was used to prevent proliferation and scarring in the early postoperative period. Results. At the follow-up period of 6 months after the operation, the drainage outflow tracts were preserved; intraocular pressure was stabilized. Conclusions. Microinvasive non-penetrating sclerectomy with Healaflow injection is the safe and effective method of surgical treatment of patients with postveal uncompensated glaucoma. The use of Healaflow is an effective method for preventing scarring of formed drainage outflow tracts

Efficient NIR Emission from Nd, Er, and Tm Complexes with Fluorinated Selenolate Ligands

(DME)₂Ln­(SeC₆F₅)₃ (Ln = Nd, Er, Tm) can be isolated in high yield by reductive cleavage of the Se–Se bond in (SeC₆F₅)₂ with elemental Ln in DME. All three Ln compounds are isostructural, with 8 coordinate Ln bound to four O from DME, three terminally bound Se­(C₆F₅), and a dative bond from an arene fluoride to a fluorine at the ortho position of one selenolate. Emission measurements indicate that these compounds are bright NIR sources